Dr Reddy’s Launches Heartburn Drug in US Market
Dr Reddy’s Laboratories launched Omeprazole delayed-release tablets, used to treat frequent heartburn, in the US market. “Dr Reddy’s Laboratories has launched Omeprazole delayed-release tablets in the strength of 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec tablets, in the US,” the company said in a BSE filing.
Milan Kalawadia, Dr Reddy’s Laboratories vice president and head, US OTC and Speciality Rx businesses, said this launch illustrated the company’s continued commitment to the OTC business as well as the depth and breadth of its OTC portfolio.
Cadila arm gets USFDA nod for ulcer treatment injection
Drug firm Cadila Healthcare on Tuesday said its subsidiary had received approval from the US health regulator to market Ranitidine injection, used to treat stomach and duodenal ulcers. Liva Pharmaceu-ticals, a wholly-owned subsidiary of Cadila Healthcare, has received approval from the USFDA for its supplemental abbreviated new drug application, Ranitidine Injection USP, 25 mg/mL, 2 mL single dose vials and 6 mL multi-dose vials, Cadila Healthcare said.
